Home Newsfeeds Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis

Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922

byCharles Gross

July 1, 2022

1 minute read

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922

Australia’s Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions

By Lara Goldstein

February 7, 3:05 PM

As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the

NUMIF

Piper Sandler Maintains Neutral on Asana, Lowers Price Target to $13

By Benzinga Newsdesk

January 9, 7:30 AM

Piper Sandler analyst Brent Bracelin maintains Asana (NYSE:ASAN) with a Neutral and lowers the price target from $16 to $13.

ASAN

Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback

By Vandana Singh

September 2, 1:41 PM

Raymond James initiated coverage on AnaptysBio Inc (NASDAQ:ANAB) with an Outperform rating and a $35 price target. The analyst has a positive…

ANAB

Barclays Plots Roadmap Of EV ‘Megatrends’: Why Tesla Is King, Rivian Is Runner-Up And The Wheels Are Turning At Ford, GM

By Adam Eckert

February 15, 3:11 PM

Barclays is out with extensive coverage on several automakers Wednesday. Here's a look at the key initiations and the main drivers behind the firm's multifaceted call.

Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis

Related Posts

Australia’s Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions

Piper Sandler Maintains Neutral on Asana, Lowers Price Target to $13

Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback

Barclays Plots Roadmap Of EV ‘Megatrends’: Why Tesla Is King, Rivian Is Runner-Up And The Wheels Are Turning At Ford, GM